Epigenetics of Immunity in Cancer
- Project duration: September 2019 - March 2022
- Project status: Ongoing
- Funding: Italy-Austria 2014-2020 (EUTC / EU funding / Project)
- Total project budget: €216,404.00
"Cancer inhibitors" in immune therapy: initiation of a promising research project
Cancer is characterized by uncontrolled cell growth, which can spread to otherwise healthy tissue and organs. Only five to ten percent of cancers are caused by inherited genetics, the majority of the cases are triggered by external factors such as tobacco consumption, diet, infections, or radiation. These external factors may induce so-called epigenetic changes, which may result in cancer cells being no longer recognized by the immune system. Cancer cells thus "hide" from the immune system.
However, some of these epigenetic changes are reversible, and that's where the scientists are going to act on. Utilizing inhibitory compounds (in short, inhibitors) allows prevention of these changes and reactivate previously deactivated genes, so that the immune system can retake action and remove degenerated cells.
The "Epigenetics of Immunity in Cancer" (EPIC) project was started in September 2019, focusing on histone deacetylase (HDAC) inhibitors. The research team comprises of chemists, clinicians, biologists, and bioinformaticians from the universities of Udine, Salzburg, and Trieste, as well as the Institute for Biomedicine at Eurac Research in Bolzano. The team is testing the effect of HDAC inhibitors in cancer cells and their suppressive role in tumor progression. In particular, the University of Udine is checking HDAC inhibition based on a library of HDAC compounds, whereas the University of Trieste is optimizing promising compounds with the aid of computer programs followed by their synthesis. At the University of Salzburg, selected inhibitors are being tested in cell models with respect to their influence on the immune system. Data generated by all partners are shared with bioinformaticians at Eurac Research, who are tasked with their analysis. Invoking next generation sequencing methods, the differences between cancer cells with and without inhibitors are measured: which genes are active, where are they active and what consequences could these compounds have in the human organism. Data obtained from theses analyses are compared to international databases in order to gain additional knowledge on cancer development. In this way, the three-year lasting project is supposed to create the basis for novel advances in cancer immune therapy.
University of Trieste
University of Udine
This project is funded by the European Regional Development Fund and the Interreg V-A Italia-Österreich 2014-2020.
Epigenetics of Immunity in CancerDuration: September 2019 - July 2021Funding:
CHRIS-2D: a Dynamic Data infrastructure for biomedical research and innovation in South TyrolDuration: June 2020 - July 2021Funding:
Innovative therapies for cardiovascular disease.Duration: October 2020 - July 2021Funding:
Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discoveryDuration: December 2019 - July 2021Funding: